Biomerica Inc key statistics and ratios

In fiscal 2026, Biomerica Inc had return on equity of -112.1%, an operating margin of -119.5%, debt equal to 0.0% of equity and a current ratio of 1.62. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Biomerica Inc: financial ratios, annual
Fiscal year	2011May 2011	2012May 2012	2013May 2013	2014May 2014	2015May 2015	2016May 2016	2017May 2017	2018May 2018	2019May 2019	2020May 2020	2021May 2021	2022May 2022	2023May 2023	2024May 2024	2025May 2025	2026May 2026	LTMAug 2026
Gross margin	31.1%	37.8%	37.5%	32.6%	31.1%	29.7%	34.9%	31.5%	24.8%	26.0%	5.1%	15.8%	8.4%	11.3%	9.4%	8.1%	0.9%
Operating margin	−2.7%	8.3%	7.9%	−8.7%	−13.5%	−16.1%	−16.5%	−26.6%	−46.4%	−41.0%	−104.2%	−24.0%	−135.3%	−117.6%	−96.7%	−119.5%	−125.2%
Net margin	3.2%	9.0%	8.3%	−4.2%	−6.7%	−29.2%	−15.7%	−26.3%	−46.0%	−40.0%	−103.4%	−24.0%	−133.7%	−110.4%	−93.6%	−84.8%	−115.5%
Free-cash-flow margin	3.8%	−0.3%	17.6%	−19.5%	−8.4%	−5.8%	−14.1%	−23.4%	−45.1%	−64.7%	−74.8%	−2.8%	−103.7%	−99.9%	−72.3%	−76.8%	−91.2%
Return on equity	3.6%	11.8%	9.9%	−3.7%	−5.8%	−27.7%	−18.7%	−33.3%	−57.6%	−29.4%	−63.5%	−51.6%	−71.2%	−65.3%	−93.0%	−112.1%	−159.6%
Return on assets	3.2%	10.4%	9.0%	−3.4%	−5.3%	−25.3%	−16.9%	−28.6%	−45.7%	−23.8%	−51.2%	−39.1%	−55.3%	−50.4%	−65.4%	−59.4%	−67.6%
Asset turnover	0.99	1.16	1.08	0.80	0.79	0.87	1.08	1.09	0.99	0.59	0.50	1.63	0.41	0.46	0.70	0.70	0.58
Current ratio	6.22	7.58	9.38	8.84	8.38	9.55	7.96	5.00	3.56	10.00	7.10	4.69	6.58	3.51	2.80	1.62	1.91
Debt to equity	0.0%	0.9%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	n/m	—	—	n/m	—	n/m	n/m	n/m	n/m	n/m	n/m	—	—	—	—	—	—
Effective tax rate	—	10.6%	−2.4%	—	—	—	—	—	—	—	—	—	—	—	—	—	—
R&D as % of revenue	8.6%	5.7%	7.1%	11.5%	14.8%	15.2%	19.5%	25.1%	32.3%	28.9%	30.5%	9.6%	29.7%	27.5%	19.3%	17.7%	18.0%
SG&A as % of revenue	25.3%	23.8%	22.5%	29.8%	29.8%	30.6%	31.9%	33.0%	39.0%	38.1%	78.8%	30.2%	114.0%	101.3%	86.8%	109.9%	108.1%
Capital spending as % of revenue	2.9%	2.7%	4.0%	2.7%	0.2%	1.8%	1.7%	2.3%	1.9%	0.5%	1.9%	0.3%	1.2%	0.9%	0.0%	0.0%	0.0%
Free cash flow ÷ net income	119.2%	−3.2%	211.7%	—	—	—	—	—	—	—	—	—	—	—	—	—	—

US$ thousands unless shown otherwise. Fiscal quarters.

Biomerica Inc: financial ratios, quarterly
Quarter	2025 Q2Nov 2024	2025 Q3Feb 2025	2025 Q4May 2025	2026 Q1Aug 2025	2026 Q2Nov 2025	2026 Q3Feb 2026	2026 Q4May 2026	2027 Q1Aug 2026
Gross margin	26.7%	1.7%	−32.6%	30.7%	4.2%	−4.5%	−8.1%	8.1%
Operating margin	−60.7%	−108.1%	−208.8%	−81.0%	−113.5%	−131.5%	−175.2%	−97.0%
Net margin	−58.1%	−103.9%	−206.1%	0.1%	−109.1%	−132.9%	−130.9%	−97.4%
Free-cash-flow margin	−48.3%	−93.4%	−88.4%	−19.4%	−81.9%	−126.6%	−104.2%	−63.4%
Current ratio	3.17	3.76	2.80	3.48	3.25	2.64	1.62	1.91
R&D as % of revenue	15.7%	19.4%	33.6%	15.4%	16.0%	18.0%	23.4%	16.3%
SG&A as % of revenue	71.7%	90.4%	142.6%	96.4%	101.7%	109.0%	143.7%	88.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 2 checks passed · August 31, 2026

What it owns · $8m

Short-term assets $5mLonger-term assets $3m

What it owes, and who funded it · $8m

Short-term liabilities $3mLonger-term liabilities $2mShareholders' equity $4m

Short-term assets cover short-term liabilities $5m of assets due within a year against $3m of liabilities due within a year.
Short-term assets cover long-term liabilities $5m short-term assets against $2m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Biomerica Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

10 /100

Weak moat

How hard Biomerica's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 0 / 20

Cash operating profit has been a median -29.8% of total assets over 10 years.
Pricing power 0 / 20

Gross margin has been a median 16.3%, moving by 10.5 percentage points (standard deviation) across 10 years.
Durability 10 / 20

Operating margin has been a median -79.9%; its worst year was -125.2%.
Cash conversion 0 / 20

Free cash flow was positive in 0 of 10 years, at a median -53.5% of revenue.
Discipline 0 / 20

The diluted share count rose 130.9% over five years; stock-based pay has been a median 11.7% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BMRA vs INBS BMRA vs CNSY BMRA vs MCTA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Biomerica Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biomerica Inc.